News
In today’s rapidly evolving digital landscape, leadership in software quality assurance is crucial to the success of any technology-driven organization. Sonali Sheetal stands as a formidable force in ...
The agreements cap patients’ monthly out-of-pocket costs for Zepbound and Wegovy at $200 and more deeply discount the drugs ...
3d
Zacks.com on MSNHere's Why You Should Hold Cigna Stock in Your Portfolio for NowCI gains 14.7% YTD as Evernorth and Cigna Healthcare drive growth, but rising expenses and debt pose challenges.
16h
WCAX on MSNHinesburg cuts ribbon on new Independent living communityOfficials held a ribbon-cutting on Wednesday for Kelley’s Field II, a new independent living community in Hinesburg.
14d
GlobalData on MSNWegovy and Zepbound costs capped at $200 in new Evernorth programmeEvernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy (semaglutide) and Zepbound (tirzepatide) will not exceed $200. Wegovy has a ...
Evernorth has capped antiobesity drug monthly co-pays at $200 in a move to improve access and affordability amid new drug ...
The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.
UBS analyst AJ Rice reaffirmed a “Buy” rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views ...
Health plan sponsors are also expected to see a reduction in the net cost per prescription of GLP-1 medications to treat obesity.
Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to ...
Cigna’s (NYSE:CI) health services arm, Evernorth, has launched a pharmacy benefit program that caps out-of-pocket costs at $200 per month for patients using the weight-loss drugs - Wegovy from Novo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results